title: Evaluation of breast cancer susceptibility loci on 2q35, 3p24, 17q23 and FGFR2 genes in Taiwanese women with breast cancer.
abstract: OBJECTIVE
  Breast cancer is the most common cancer in women. In recent years, mounting evidence has identified the possibility that 2q35, 3p24, 17q23 and fibroblast growth factor receptor 2 (FGFR2) may be genetic susceptibility loci for breast cancer. This study aimed to evaluate the association of four polymorphic genotypes in these loci with breast cancer in Taiwanese women.
  
  
  METHODS
  Eighty-eight patients with breast cancer and 70 controls without breast cancer were selected. Polymorphic variants of 2q35-rs13387042, 3p24-rs4973768, 17q23-rs650490 and FGFR2-rs2981578 were analyzed to test for their association with breast cancer susceptibility. The 2q35, 17q23 and FGFR2 polymorphisms were detected using polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) and the 3p24 polymorphism was detected using an amplification-created restriction site method.
  
  
  RESULTS
  The distribution of genotypes of 2q35 were significantly different between the breast cancer group and the control group (p=0.035), while the distributions for 3p24, 17q23, and FGFR2 did not produce statistically significant differences (p>0.05). In addition, allele A of 2q35 conferred a higher risk for breast cancer risk than allele G (odds ratio, OR=2.95, 95% confidence interval, CI=1.29-6.71, p=0.008). Furthermore, the genotypic distribution of 2q35 was not significantly different among patients with different tumor stages, or from different specimen type.
  
  
  CONCLUSIONS
  The 2q35 allele A may be a potential biomarker for breast cancer risk, but further confirmation is required to determine its role in breast carcinogenesis. Blood samples can be used for determining the genotypes for 2q35-rs13387042 in patients for risk of breast cancer.
authors.affiliation: Department of Laboratory Medicine, Linkou Chang-Gung Memorial Hospital, 5 Fu-Hsin Street, Kweishan, Taoyuan 333, Taiwan, ROC.
authors.forename: Chien-Yu
authors.initials: CY
authors.lastname: Lin
authors.forename: Cheng-Mao
authors.initials: CM
authors.lastname: Ho
authors.forename: Da-Tian
authors.initials: DT
authors.lastname: Bau
authors.forename: Shu-Fen
authors.initials: SF
authors.lastname: Yang
authors.forename: Shu-Hui
authors.initials: SH
authors.lastname: Liu
authors.forename: Po-Han
authors.initials: PH
authors.lastname: Lin
authors.forename: Tsai-Hsiu
authors.initials: TH
authors.lastname: Lin
authors.forename: Ni
authors.initials: N
authors.lastname: Tien
authors.forename: Mu-Chin
authors.initials: MC
authors.lastname: Shih
authors.forename: Jang-Jih
authors.initials: JJ
authors.lastname: Lu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D001943:Breast Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D002900:Chromosomes, Human, 1-3; D002886:Chromosomes, Human, Pair 17; D002889:Chromosomes, Human, Pair 2; D002893:Chromosomes, Human, Pair 3; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide; D051497:Receptor, Fibroblast Growth Factor, Type 2 / Q000235:genetics* / Q000378:metabolism; D013624:Taiwan
chemical_list: C496353:FGFR2 protein, human; D051497:Receptor, Fibroblast Growth Factor, Type 2